Marsh & McLennan: A $100B Giant Underperforming?

Marsh and McLennan: Is This Insurance Giant a Bargain Buy? Despite strong earnings, the $100B+ risk and insurance powerhouse is underperforming, down nearly 10% this year while competitors soar. We dive into why the stock is lagging, analyst outlooks, and whether its 14% potential upside makes it a smart investment. Hosted on Acast. See acast.com/privacy for more information.